Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Total Non-Current Liabilities of $197.8 million for Q1 2026, down 13.69% year-on-year from $229.2 million in Q1 2025, and down 2.37% on a QoQ basis from $202.6 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Total Non-Current Liabilities data on file, last reported at $197.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 13.69% year-over-year to $197.8 million; the trailing twelve-month figure through Mar 2026 stood at $197.8 million (down 13.69% YoY), and the FY2025 full-year result was $215.8 million, down 12.86% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $197.8 million, down from $202.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $256.9 million in Q2 2023 and bottomed at $46.3 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $221.5 million (2025), against an average of $178.6 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities slipped 17.17%; it then jumped 448.55% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $46.3 million in 2022, then surged by 409.83% to $236.0 million in 2023, then rose by 0.26% to $236.6 million in 2024, then slipped by 14.35% to $202.6 million in 2025, then decreased by 2.37% to $197.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $197.8 million (Q1 2026), $202.6 million (Q4 2025), and $215.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 197.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.84 Mn |
| Dec 31, 2025 | 202.64 Mn |
| Sep 30, 2025 | 215.76 Mn |
| Jun 30, 2025 | 221.50 Mn |
| Mar 31, 2025 | 229.21 Mn |
| Dec 31, 2024 | 236.59 Mn |
| Sep 30, 2024 | 247.61 Mn |
| Jun 30, 2024 | 249.68 Mn |
| Mar 31, 2024 | 247.22 Mn |
| Dec 31, 2023 | 235.97 Mn |
| Sep 30, 2023 | 244.12 Mn |
| Jun 30, 2023 | 256.92 Mn |
| Mar 31, 2023 | 56.66 Mn |
| Dec 31, 2022 | 46.28 Mn |
| Sep 30, 2022 | 52.65 Mn |
| Jun 30, 2022 | 46.84 Mn |
| Mar 31, 2022 | 47.89 Mn |
| Dec 31, 2021 | 55.87 Mn |
| Sep 30, 2021 | 37.86 Mn |
| Jun 30, 2021 | 32.27 Mn |
| Mar 31, 2021 | 31.43 Mn |
| Dec 31, 2020 | 28.04 Mn |
| Sep 30, 2020 | 29.07 Mn |
| Jun 30, 2020 | 30.09 Mn |
| Mar 31, 2020 | 26.47 Mn |
| Dec 31, 2019 | 27.01 Mn |
| Sep 30, 2019 | 25.86 Mn |
| Jun 30, 2019 | 22.13 Mn |
| Mar 31, 2019 | 23.45 Mn |
| Dec 31, 2018 | 25.43 Mn |
| Sep 30, 2018 | 18.92 Mn |
| Jun 30, 2018 | 16.69 Mn |
| Mar 31, 2018 | 21.05 Mn |
| Dec 31, 2017 | 20.75 Mn |
| Sep 30, 2017 | 24.20 Mn |
| Jun 30, 2017 | 14.80 Mn |
| Mar 31, 2017 | 12.79 Mn |
| Dec 31, 2016 | 8.95 Mn |
| Sep 30, 2016 | 11.18 Mn |
| Jun 30, 2016 | 12.26 Mn |
| Mar 31, 2016 | 13.80 Mn |
| Dec 31, 2015 | 13.98 Mn |
| Sep 30, 2015 | 8.14 Mn |
| Jun 30, 2015 | 9.39 Mn |
| Mar 31, 2015 | 21.58 Mn |
| Dec 31, 2014 | 21.48 Mn |
| Sep 30, 2014 | 6.53 Mn |
| Jun 30, 2014 | 4.89 Mn |
| Mar 31, 2014 | 5.01 Mn |
| Dec 31, 2013 | 4.39 Mn |
| Sep 30, 2013 | 184,000.00 |
| Jun 30, 2013 | 3.48 Mn |
| Mar 31, 2013 | 6.82 Mn |
| Sep 30, 2012 | 423,000.00 |